Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration

ISSN： 1751-2433

Source： Expert Review of Clinical Pharmacology, Vol.6, Iss.2, 2013-03, pp. : 103-113

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Current and Future Treatment Options for Nonexudative and Exudative Age-Related Macular Degeneration

By Grant M. Comer

Drugs & Aging, Vol. 21, Iss. 15, 2004-01 ,pp. : 967-992

Adis International

Access to resources Recommend Favorite

Future pharmacological treatment options for nonexudative and exudative age-related macular degeneration

By Comer Grant M Ciulla Thomas A Heier Jeffery S Criswell Mark H

Expert Opinion on Emerging Drugs, Vol. 10, Iss. 1, 2005-02 ,pp. : 119-135

Informa Healthcare

Access to resources Recommend Favorite

Pegaptanib: In Exudative Age-Related Macular Degeneration

By Siddiqui M. Asif A. Keating Gillian M.

Drugs, Vol. 65, Iss. 11, 2005-01 ,pp. : 1571-1577

Adis International

Access to resources Recommend Favorite

VEGF inhibitors for the treatment of neovascular age-related macular degeneration

By Barakat Mark Rami Kaiser PK

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 5, 2009-05 ,pp. : 637-646

Informa Healthcare

Access to resources Recommend Favorite

VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration

By Lazzeri Stefano Figus Michele Orlandi Paola Fioravanti Anna Di Desidero Teresa Agosta Elisa Sartini Maria Sole Posarelli Chiara Nardi Marco Danesi Romano Bocci Guido

Pharmacogenomics, Vol. 14, Iss. 6, 2013-04 ,pp. : 623-630

Future Medicine

Access to resources Recommend Favorite